超跌反彈?醫藥股集體走強,貝康醫療-B(2170.HK)大漲近7%
格隆匯9月6日丨受A股醫藥股集體大漲帶動,港股市場醫藥股跟隨走強。其中,輔助生殖器械龍頭貝康醫療-B(2170.HK)一度漲6.67%至12.8港元,市值35億港元。在經過此前的持續調整後,醫藥板塊今日為何迎來久違的上漲行情?有分析人士指出,面對高景氣賽道(醫藥)的大幅調整,市場上的主流研究機構近期均頻頻發聲,在板塊回調下建議積極佈局,把握住高景氣板塊估值的回調窗口。其中,國海證券在最新報吿中稱,醫藥醫療龍頭估值進入合理區間,看好板塊行情超跌下的反彈行情。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.